相关临床试验
22
2 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
1
4.5%
已完成
15
68.2%
尚未招募
1
4.5%
招募中
2
9.1%
终止
2
9.1%
Unknown
1
4.5%
暂无批准数据
- Nearly 1 in 3 U.S. adults without heart disease have LDL cholesterol above the new 2026 ACC/AHA guideline goals, and about 76% of them are not receiving any cholesterol-lowering medication. - Among adults with established cardiovascular disease, nearly 4 in 5 are above the recommended LDL targets, with 38% receiving no treatment at all. - The 2026 guideline expands primary prevention statin eligibility to an additional 21.5 million Americans, bringing the total to 87.5 million (56.6% of adults aged 30–79). - Newly eligible populations are predominantly younger and lower risk, including nearly 20 million individuals with less than 3% estimated 10-year ASCVD risk.
- TrivarX received Institutional Review Board approval to begin a 60-patient clinical trial screening for current major depressive episodes using AI technology in partnership with the US Department of Veterans Affairs. - The trial will test whether TRI's AI algorithm can effectively detect mental health conditions through sleep data using single-channel ECG technology compatible with wearable devices like smartwatches. - Previous Phase 2 studies demonstrated promising results with 87% sensitivity and 67% specificity in identifying current major depressive episodes, potentially addressing the growing mental health crisis that has seen claims surge from $1.2 billion to $2.2 billion between 2019-2024.
